In brief
Ahmed Elhusseiny of Roche argues that the pandemic taught healthcare in Asia Pacific that it must shift from treating illness after it appears to preventing it, with personalised care built on data and digital tools. He says the tools already exist, and the real challenge is putting them into practice through partnerships.
The episode moves from the pandemic's damage, such as disrupted care and backlogs, to its upside: faster regulation, telehealth and data use. The tension is that crisis-driven partnerships were easy to form because the need was urgent, whereas ageing-population challenges need long-term commitment and clear alignment among partners..
Questions
What does personalised healthcare mean?
Ahmed Elhusseiny describes it as tailoring care to each person's characteristics, such as genetics, gender and age, instead of giving everyone the same regimen. The aim is the right care at the right time.
How did the pandemic change healthcare in Asia Pacific?
It disrupted care for conditions like diabetes and cancer, but it also sped up regulatory approvals, telehealth and large-scale use of data. Elhusseiny sees the second part as a basis for future innovation.
How would we know if personalised healthcare is working?
Elhusseiny says success would show in longer and better-quality lives, less disability, and fewer and shorter hospital stays. It would also make the healthcare system more efficient.
What is Roche doing in Asia Pacific?
Elhusseiny says Roche, a 125-year-old Swiss company, has manufacturing, research and development, commercial and medical services across the region. His own role focuses on widening patient access to therapies.
Why does he say partnerships are hard but necessary?
He says challenges like an ageing population are too big for any one party. The difficulties are aligning on outcomes and sustaining long-term commitment, which the acute COVID crisis did not require.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Roche is a Swiss company about 125 years old, according to Ahmed Elhusseiny, with a global footprint including Asia Pacific.
“This is a 125-year-old company. It's a Swiss company, but it's truly a global company with a global footprint, including, of course, in Asia Pacific.”
0:05:23 · Ahmed Elhusseiny · Roche history
Roche's stated mission, per Ahmed Elhusseiny, is doing now what patients need next.
“Our mission is around doing now what patients need next.”
0:05:23 · Ahmed Elhusseiny · Roche mission
Ahmed Elhusseiny says Roche's motto is first in class, best in class.
“Our motto is first in class, best in class.”
0:05:55 · Ahmed Elhusseiny · Roche motto
Roche consists of two broad parts, Roche Pharmaceuticals and Roche Diagnostics, according to Ahmed Elhusseiny.
“Roche, broadly speaking, is also Roche Pharmaceuticals and Roche Diagnostics.”
0:06:27 · Ahmed Elhusseiny · Roche structure
Ahmed Elhusseiny says Roche's presence in Asia spans manufacturing, research and development, commercialization and medical services.
“our presence extends from manufacturing to research and development and, of course, commercialization and medical services to patients all over the region.”
0:06:27 · Ahmed Elhusseiny · Roche Asia presence
Ahmed Elhusseiny holds a PhD in neuroscience and began his industry career in biotech clinical research.
“I did a PhD in neuroscience.”
0:02:36 · Ahmed Elhusseiny · Career background
Ahmed Elhusseiny is originally from Egypt and is also Canadian.
“I'm originally from Egypt, but I'm also Canadian.”
0:02:36 · Ahmed Elhusseiny · Career background
Ahmed Elhusseiny says COVID-19 disrupted almost every care pathway, including diabetes and cancer care.
“it had also broader impact on the healthcare system as a whole. And this really impacted almost every care pathway that exists.”
0:09:42 · Ahmed Elhusseiny · Pandemic impact · 2020
Ahmed Elhusseiny says regulatory approval pathways for healthcare products were accelerated because of COVID-19.
“even things like regulatory approval and the pathways by which products get reviewed. Those were absolutely accelerated because of COVID”
0:10:37 · Ahmed Elhusseiny · Regulatory approval · 2020
Malaysia and Singapore used track and trace apps during the pandemic, according to Ahmed Elhusseiny.
“If you lived in Malaysia or in Singapore, of course, you had the track and trace apps.”
0:11:51 · Ahmed Elhusseiny · Contact tracing · 2020
Ahmed Elhusseiny says South Korea used other data sources, such as buying patterns, to track the pandemic.
“in Korea, they were also using other data sources to be able to track the pandemic. So buying patterns, for example.”
0:11:51 · Ahmed Elhusseiny · Pandemic tracking · 2020
Roche partnered with the World Health Organization to allocate one of its products fairly during the pandemic, according to Ahmed Elhusseiny.
“One example is a partnership we did with the WHO to allocate one of our products and to make sure that the allocation of this product is as fair and just as possible.”
0:13:04 · Ahmed Elhusseiny · WHO partnership · 2020
In Thailand, Roche partnered with local associations to provide COVID testing in remote areas using tuk-tuks.
“in Thailand, we partnered with local associations there to really be able to provide COVID testing in remote areas using tuk-tuks.”
0:13:41 · Ahmed Elhusseiny · COVID testing
Malaysia's track and trace app, called MySejahtera in the show notes' context, was originally built for tracking and is being repurposed for health records.
“the track and trace app in Malaysia, which is called MySejHarta, it was initially, of course, developed to be able to to track, but now is being repurposed”
0:17:49 · Ahmed Elhusseiny · MySejahtera app
The Malaysian app is being extended to record vaccination records and blood glucose levels, which could help diabetes care.
“including vaccination records and also blood glucose levels, which of course then can have potential”
0:17:49 · Ahmed Elhusseiny · MySejahtera app
Ahmed Elhusseiny says teleconsultation technologies are being repurposed for telementoring and skills building for healthcare professionals in Asia.
“Those technologies are now being repurposed for things like telementoring and building skills and capabilities for healthcare professionals around Asia.”
0:17:49 · Ahmed Elhusseiny · Telemedicine
Ahmed Elhusseiny describes the ageing population in Asia Pacific as a slowly creeping epidemic bringing diseases such as Alzheimer's and cardiovascular disease.
“In the APAC region, the aging population is a slowly creeping pandemic or epidemic.”
0:15:29 · Ahmed Elhusseiny · Ageing population
Ahmed Elhusseiny says personalised healthcare would tailor treatment to a person's genetic profile and background rather than giving everyone the same regimen.
“based on your genetic profile, based on your background, your healthcare, you would get something different based on that than I would.”
0:22:46 · Ahmed Elhusseiny · Personalised healthcare
Ahmed Elhusseiny says personalised healthcare combines medical science, digital technology and data science.
“Personalized healthcare brings together medical science, digital technology, and data science.”
0:24:21 · Ahmed Elhusseiny · Personalised healthcare
Ahmed Elhusseiny says personalised healthcare would be measurable partly through lower hospitalisation rates and shorter hospital stays.
“we could see people staying shorter periods in hospitals. So hospitalization rates would go down.”
0:24:49 · Ahmed Elhusseiny · Healthcare metrics
Ahmed Elhusseiny recommended the book In the Dragon's Shadow, about the interplay between China and the Asia-Pacific region.
“I'm actually reading a book called In the Dragon's Shadow, which actually is very topical for the region I'm in right now.”
0:26:43 · Ahmed Elhusseiny · Book recommendation